Investigational New Drugs

Published by: Springer  

People

  1. Motzer
    Motzer
  2. Bajorin
    Bajorin
  3. Kelsen
    Kelsen
  4. Bosl
    Bosl
  5. Feldman
    Feldman
  6. Lacouture
    Lacouture
  7. Ginsberg
    Ginsberg
  8. Scher
    Scher
  9. Gounder
    Gounder
  10. Heelan
    Heelan

Groups

  1. Department of Medicine (94)
  2. Solid Tumor Oncology Division (87)
  3. Genitourinary Oncology Service (40)
  4. Gastrointestinal Oncology Service (24)
  5. Survivorship Research (18)
  6. Center for Pancreatic Cancer Research (17)
  7. Radiology, Department of (15)
  8. Hematologic Malignancies, Division of (13)
  9. Surgery (12)
  10. Body Imaging Service (11)
Search Within
Formats
  1. Journal Article (111)
  2. Meeting Abstract (5)
Groups
  1. Department of Medicine (94)
  2. Solid Tumor Oncology Division (87)
  3. Genitourinary Oncology Service (40)
  4. Gastrointestinal Oncology Service (24)
  5. Survivorship Research (18)
  6. Center for Pancreatic Cancer Research (17)

More Groups

People
  1. Robert Motzer (19)
  2. David Kelsen (10)
  3. Dean Bajorin (10)
  4. Ephraim Casper (10)
  5. Gary Schwartz (8)
  6. George Bosl (8)

More People

Years
  1. 2022 (2)
  2. 2021 (7)
  3. 2020 (7)
  4. 2019 (5)
  5. 2018 (7)
  6. 2017 (2)

More Years

Publishers
  1. Springer (116)

Results (116)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
    Journal Article

    Calvo, E.; Sessa, C.; Harada, G.; de Miguel, M.; Kahatt, C.; Luepke-Estefan, X. E.; Siguero, M.; Fernandez-Teruel, C.; Cullell-Young, M.; Stathis, A.; more...
    Investigational New Drugs (2022)

    Fulltext@MSK | Save
  • A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors
    Journal Article

    Adra, N.; Vaughn, D. J.; Einhorn, L. H.; Hanna, N. H.; Funt, S. A.; Rosales, M.; Arozullah, A.; Feldman, D. R.
    Investigational New Drugs (2022)

    Fulltext@MSK | Save
  • Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors
    Journal Article

    Ashkar, R.; Feldman, D. R.; Adra, N.; Zaid, M. A.; Funt, S. A.; Althouse, S. K.; Perkins, S. M.; Snow, C. I.; Lazzara, K. M.; Sego, L. M.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
    Journal Article

    Zauderer, M. G.; Alley, E. W.; Bendell, J.; Capelletto, E.; Bauer, T. M.; Callies, S.; Szpurka, A. M.; Kang, S.; Willard, M. D.; Wacheck, V.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors
    Journal Article

    Azaro, A.; Massard, C.; Tap, W. D.; Cassier, P. A.; Merchan, J.; Italiano, A.; Anderson, B.; Yuen, E.; Yu, D.; Oakley, G. 3rd; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • Characterization and management of ERK inhibitor associated dermatologic adverse events: Analysis from a nonrandomized trial of ulixertinib for advanced cancers
    Journal Article

    Wu, J.; Liu, D.; Offin, M.; Lezcano, C.; Torrisi, J. M.; Brownstein, S.; Hyman, D. M.; Gounder, M. M.; Abida, W.; Drilon, A.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • A decision process for drug discovery in retinoblastoma
    Journal Article

    Cancela, M. B.; Zugbi, S.; Winter, U.; Martinez, A. L.; Sampor, C.; Sgroi, M.; Francis, J. H.; Garippa, R.; Abramson, D. H.; Chantada, G.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer
    Journal Article

    Gartrell, B. A.; Roach, M. 3rd; Retter, A.; Sokol, G. H.; Del Priore, G.; Scher, H. I.
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)
    Journal Article

    Hecht, J. R.; Papadopoulos, K. P.; Falchook, G. S.; Patel, M. R.; Infante, J. R.; Aljumaily, R.; Wong, D. J.; Autio, K. A.; Wainberg, Z. A.; Bauer, T. M.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
    Journal Article

    Rowinsky, E. K.; Paner, A.; Berdeja, J. G.; Paba-Prada, C.; Venugopal, P.; Porkka, K.; Gullbo, J.; Linder, S.; Loskog, A.; Richardson, P. G.; more...
    Investigational New Drugs (2020)

    Fulltext@MSK | Save

    • Investigational New Drugs – authorized name for:

    Name ISSN / ISBN Publisher
    Investigational New Drugs 01676997 Springer Science + Business Media, LLC
    Investigational New Drugs 0167-6997 Unknown
    Investigational New Drugs 01676997 Kluwer Academic Publishers
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 01676997 Springer
    Investigational New Drugs 0167-6997 Kluwer Academic Publishers
    Investigational New Drugs 01676997 Springer Science + Business Media, LLC
    Investigational New Drugs 0167-6997 Martinus Nijhoff Publishers
    Investigational New Drugs 01676997 2020, The Author(s)
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 15730646 Springer Science + Business Media, LLC
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 15730646 Unknown
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 15730646 Springer Science + Business Media, LLC
    Investigational New Drugs 01676997 2019, Springer Science+business Media, Llc, Part of Springer Nature
    Investigational New Drugs 01676997 2019, The Author(s)
    Investigational New Drugs 01676997 Springer Science + Business Media, LLC
    Investigational New Drugs 01676997 Springer Science + Business Media, LLC
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 01676997 Unknown
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 01676997 Springer Science + Business Media, LLC
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 01676997 2017, Springer Science+business Media New York
    Investigational New Drugs 01676997 Springer Science + Business Media, LLC
    Investigational New Drugs 01676997 Springer Science+Business Media New York
    Investigational New Drugs 01676997 The Author(s)
    Investigational New Drugs 01676997 Springer
    Investigational New Drugs 01676997 2018, The Author(s)
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 0167-6997 Kluwer Academic Publishers
    Investigational New Drugs: An Interdisciplinary Journal for Clinicians and Scientists 01676997 Unknown